Early economic benefits of gene expression profiling using a 21-gene panel among breast cancer patients

Published in conjunction with the 2016 ASCO Annual Meeting

Gene expression profiling utilizing a 21-gene panel assay among breast cancer patients with early stage, axillary lymph node negative, hormone receptor positive, HER2/neu oncogene negative tumors is able to identify a cohort with excellent long term outcomes without adjuvant chemotherapy. Although economic models have suggested acceptable QALY ratios, “real world” confirmation is scant and few studies have focused on the short-term costs important in value-based payment reform.

Authors: Stanley E. Waintraub, Donna M. McNamara, Deena Atieh Graham., Andrew Pecora, John Min, Tommy Wu, Hyun gi Noh, Jacqueline Connors, Ruth Pe Benito, Kelly Choi, Eric V Schultz, Stuart L. Goldberg; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; COTA, New York, NY

Thank you signing up!
Oops! Something went wrong while submitting the form